Noxopharm Ltd. · ASX:NOX
Noxopharm — Non-Deal Roadshow (April 2020)
21 slides from Noxopharm's roadshow presentation, Apr 2, 2020
Slide 1: Updated Noxopharm Virtual Roadshow Corporate Presentation
For personal use only 2 April 2020 Sydney, Australia Updated Noxopharm Virtual Roadshow Corporate Presentation Sydney, 2 April 2020: Noxopharm (ASX: NOX) is pleased to provide shareholders and the market the attached Noxopharm “Updated Non-Deal Roadshow Corporate Presentation”. This updated document
Slide 2: Forward Looking Statements (continued)
For personal use only uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. Suite 3, Level 4, 828 Pacific Highway, Gor
Slide 3: Updated Non-Deal Roadshow Presentation
April 2020 For personal use only Noxopharm Limited Veyonda® Updated Non-Deal Roadshow Presentation DISCOVER DEVELOP DELIVER ASX: NOX © 2020 Noxopharm Ltd. All rights reserved.
Slide 4: Disclaimer
Disclaimer This presentation has been prepared by Noxopharm Limited (NOX or the Company). It should not be considered as an offer or invitation to subscribe for, or purchase any shares in NOX, or as an inducement to purchase any shares in NOX. No agreement to subscribe for securities in NOX For pers
Slide 5: Contents
Contents For personal use only Introduction Investment Highlights COVID-19 program Veyonda® Clinical Strategy Commercial Strategy Market Opportunities © 2020 Noxopharm Ltd. All rights reserved.
Slide 6: Introduction
Introduction Technology platform For personal use only q isoflavonoid molecular structure offering new generation of therapeutics built around polypharma actions (tyrosine and serine-threonine kinase inhibition) and restriction to prion-like (abnormal functioning) kinase targets Proprietary IP q str
Slide 7: Investment Case
Investment Case Veyonda® being positioned for the largest sector in the oncology market For personal use only - end-stage cancer where treatment limited to palliative care - little competition - multi-billion $ market opportunity Veyonda® immediate goal is late-stage prostate cancer - estimated 300,
Slide 8: COVID-19 Program
COVID-19 Program For personal use only Ø Death due primarily to multi-organ failure associated with abnormally excessive immune and inflammatory responses Ø Particularly lung failure from acute respiratory distress syndrome (ARDS) Ø Organ failure caused by excessive production of inflammatory protei
Slide 9: COVID-19: rationale for cytokine inhibitors such as IL-6 Inhibitors
COVID-19: rationale for cytokine inhibitors such as IL-6 Inhibitors For personal use only Patients with high level of IL-6 are less likely to survive SARS-COV2 (COVID-19) virus infection Zhou et al. 11 March 2020. Clinical course and risk factors for mortality of adult in patients with COVID-19 in W
Slide 10: COVID-19 Hudson Institute of Medical Research (HIMR)
COVID-19 For personal use only Hudson Institute of Medical Research (HIMR) Ø 18-month collaboration with NOX to determine range of immuno-oncology functions of idronoxil Ø IL-6 inhibition known and thought to contribute to anti-cancer function Ø HIMR discovers idronoxil has broader effects than on I
Slide 11: COVID-19 Next Steps
COVID-19 Next Steps For personal use only Funding Ø Company to seek non-dilutive funding. Overseas governments funding a number of trials Ø Funding would allow assembly of dedicated COVID-19 team under Dr Mautner and production of sufficient quantities of drug for some thousands of patients Clinical
Slide 12: Clinical Strategy for Prostate Cancer
Clinical Strategy for Prostate Cancer Ø Main objective: For personal use only To provide a clinical data package that is attractive for future commercial partners Ø Implementation Steps: ― First Prostate Cancer clinical trial (DARRT-1) has finished and was successful ― Second Prostate Cancer clinica
Slide 13: Which Market Segment does Veyonda occupy?
Which Market Segment does Veyonda occupy? For personal use only Course of Disease and Treatment Journey for Stage I - IV Prostate Cancer Surgery Chemical Androgen Chemo- Palliative therapy and/or local castration & receptor Rising PSA levels in blood therapy radiotherapy therapy inhibitors Veyonda®
Slide 14: Veyonda – What does the Clinical Data show?
1 Veyonda® – What does the Clinical Data show? For personal use only Ø 26 men enrolled with late-stage prostate cancer Ø Metastatic castration-resistant prostate cancer (mCRPC) Ø Progressive disease Ø No remaining standard treatment options Ø Eligible for palliative RT for symptomatic relief Ø Treat
Slide 15: DARRT-1: Does Veyonda work?
11 DARRT-1: Does Veyonda work? Ø In the 15* patients who were evaluable at 6 For personal use only months1 The Tumours stopped growing or reduced in size in 10 patients (1 patient achieved a partial response and 9 achieved stable disease at 6 months) Overall (RECIST1.1) N=10 N=5 N=15 Complete respon
Slide 16: What is the Aim of the next Trial?
2 What is the Aim of the next Trial? Ø Objectives: For personal use only ― The DARRT-2 trial is designed to provide the data that Commercial Partners are looking for ― It also aims to satisfy the Regulatory Authorities Ø Building on the experience and data of DARRT-1 Ø Phase 2 trial; multinational Ø
Slide 17: Additional Opportunity in Prostate Cancer
Additional Opportunity in Prostate Cancer For personal use only External Radiation Internal Radiation Ø Standard-of-Care Ø Experimental Ø Widely used Ø Billion-dollar Acquisition by Novartis DARRT LuPIN © 2020 Noxopharm Ltd. All rights reserved.
Slide 18: LuPIN Trial: Key Interim Results
LuPIN Trial: Key Interim Results v Veyonda® + 177Lu-PSMA-617 For personal use only § Overall Survival (OS) is a measure of the time from the start of treatment until death. 17.1 months ü Median OS was 17.1 months – a remarkable result at this late stage of the disease ü The combination therapy was w
Slide 19: Commercial Strategy
2 Commercial Strategy For personal use only Noxopharm commercial priorities 1. Attract potential partners by continuing DARRT-2 Phase 2 clinical trial to undertake clinical trials to develop planning underway Veyonda® as standard of care in treatment of prostate cancer 2. Develop alliances to streng
Slide 20: Market Opportunity
2 Market Opportunity Prostate cancer market opportunity For personal use only • 33,330 prostate cancer deaths are forecast in the US in 2020* • Potentially all of these patients could benefit from treatment with Veyonda® • The potential global demand of late stage cancer patients for multiple cycles
Slide 21: For further information please visit www.noxopharm.com
For personal use only For further information please visit www.noxopharm.com Veyonda® DISCOVER DEVELOP DELIVER ASX: NOX © 2020 Noxopharm Ltd. All rights reserved.